Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...
Stories by SWNS on MSN
Prostate cancer treatment breakthrough could boost survival rates
A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that nine ...
AUSTIN, Texas - May 14, 2026 - EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited ("Telix") ...
New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA. In this episode, ‘Comparative PSMA PET Tracer ...
Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, recurrence detection, and patient selection for radioligand therapy. Oliver Sartor, ...
In this episode, ‘Clinical Reliability of PSMA PET in Advanced Prostate Cancer,’ expert faculty examine the real-world reliability of PSMA PET imaging in evaluating tumor burden and disease extent in ...
Predicting prostate cancer (PCa) recurrence after radical treatment is crucial for personalised adjuvant therapy. This study aimed to compare different algorithms in order to select the best model for ...
The use of PSMA PET scans are useful in initial staging, detecting biochemical relapse, and eligibility for radionuclide treatment. Scott T. Tagawa, MD, identified 3 primary clinical scenarios where ...
Blogger Dan Zeller completed his fourth PSMA PET scan, which looks for a prostate-specific membrane antigen protein found on prostate cancer cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results